Jones Trading initiated coverage on Mural Oncology (NASDAQ:MURA) with a Buy rating and a price target of $16.00. Currently trading at $3.95, the stock sits well below the broader analyst target range ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) ...